


# IN THE CLAIMS

1. (previously presented) A fully and partially reduced benzo(c)quinolizine compound of formula (1):



wherein:

*not defined above.*  
 $R_1$ ,  $R_2$ ,  $R_3$ ,  $R_4$  and  $R_6$ , which are the same or different, are chosen from the group consisting of: H,  $C_{1-8}$  alkyl,  $C_{2-8}$  alkenyl,  $C_{2-8}$  alkynyl, cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, norbornane, canphane, adamantane, phenyl, biphenyl, naphthyl, or naphthyl- $C_{1-8}$ ;

$R_5$  is chosen from the group consisting of: H,  $C_{1-8}$  alkyl,  $C_{1-8}$  alkyl-phenyl, biphenyl, naphthyl, COOR, CN or phenyl,;

X is chosen from the group consisting of: O,  $C(=O)R$ , COOR,  $NO_2$ , and CONNR', wherein R and R' are as above defined;

*not defined above*  
Q is chosen from the group consisting of single-bond,  $C_{1-8}$  alkyl,  $C_{2-8}$  alkenyl,  $C_{2-8}$  alkynyl, cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, norbornane, canphane, adamantane, CO, CONR, and NR, where R is as above defined;

W is chosen from the group consisting of H,  $C_{1-8}$  alkyl,  $C_{2-8}$  alkenyl,  $C_{2-8}$  alkynyl, cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, norbornane, canphane, adamantane, trifluoromethyl,  $C_{1-8}$  alkoxy,  $C_{1-8}$  alkoxy- $C_{1-8}$  alkyl, phenyl, biphenyl, naphthyl- $C_{1-8}$  alkyl, phenyl, biphenyl, naphthyl, phenyloxy, biphenyloxy, naphthyloxy, phenylamino, biphenylamino,

naphthylamino, C<sub>1-8</sub> alkyl-carbonyl, phenylcarbonyl, biphenylcarbonyl, naphthylcarbonyl, phenylcarboxyl, biphenylcarboxyl, naphthylcarboxyl, phenylcarboxamide, biphenylcarboxamide, naphthylcarboxamide, halogen, CN, NRR', C<sub>1-8</sub> alkylamino;

n is an integer comprised between 1 and 4;

the symbol ----- means that the corresponding bonds a, b, c, d, e, f, g, h and i are single or double bonds, with the proviso that when b or f are a double bond, the group R<sub>5</sub> is absent; ~~their~~ <sup>its</sup> pharmaceutically acceptable salts and esters. ~~is this independent~~

OR

2. (previously presented) A benzo(c)quinolizine compound of formula (1) according to Claim 1, wherein R<sub>5</sub> = H, C<sub>1-8</sub> alkyl-phenyl, biphenyl, naphthyl;

X = O, COOH;

Q = single bond, CO, CONR, NR, wherein R

is chosen from the group consisting of H, C<sub>1-8</sub> alkyl, cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, norbornane, canphane, adamantane, phenyl, biphenyl, naphthyl or naphthyl-C<sub>1-8</sub>alkyl;

W = H, F, Cl, Br, Me, t-butyl, C<sub>1-8</sub>alkoxy, 2,5-dimethylhexyl, trifluoromethyl, 2,5-(di-trifluoromethyl)-phenyl, 4-methyloxy-phenyl, phenyl, phenyl-C<sub>1-8</sub>alkyl, C<sub>1-8</sub>alkylcarbonyl, phenylcarbonyl;

n = 1 and 2;

R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> and R<sub>6</sub> = H, Me, CN, phenyl, COOR, CONRR', C(=O)R, wherein R and R' are the same or different and are chosen from the group consisting of H, C<sub>1-8</sub> alkyl, cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, norbornane, canphane, adamantane, phenyl, biphenyl, naphthyl or naphthyl-C<sub>1-8</sub>

8.

3. (previously presented) A benzo[c]quinolizine compounds <sup>is this independent?</sup> according to Claim 1 of the formula:

2,3,4,4a,5,6,6a,7,8,9,10,10a-dodecahydro-(1H)-benzo[c]quinolizin-3-one;

8-chloro-2,3,4,4a,5,6,6a,7,8,9,10,10a-dodecahydro-(1H)-

benzo[c]quinolizin-3-one;  
 2,3,4,4a,5,6,6a,7,8,9,10,10a-dodecahydro-8-methyl-(1H) -  
 benzo[c]quinolizin-3-one;  
 2,3,4,4a,5,6,6a,7,8,9,10,10a-dodecahydro-4-methyl-(1H) -  
 benzo[c]quinolizin-3-one;  
 2,3,4,4a,5,6,6a,7,8,9,10,10a-dodecahydro-1-methyl-(1H) -  
 benzo[c]quinolizin-3-one;  
 2,3,4,4a,5,6,6a,7,8,9,10,10a-decahydro-(1H) -benzo[c]quinolizin-3-  
 one;  
 8-chloro-2,3,4,4a,5,6,6a,7,8,9,10,10a-decahydro-(1H) -  
 benzo[c]quinolizin-3-one;  
 2,3,4,4a,5,6,6a,7,8,9,10,10a-decahydro-8-methyl-(1H) -  
 benzo[c]quinolizin-3-one;  
 2,3,5,6,6a,7,8,9,10,10a-decahydro-4-methyl-(1H) -  
 benzo[c]quinolizin-3-one;  
 2,3,5,6,6a,7,8,9,10,10a-decahydro-1-methyl-(1H) -benzo[c]quinoli-  
 zin-3-one;  
 (4a $\alpha$ ,6a $\beta$ ,10a $\alpha$ ) -3,4,5,6,6a,7,8,9,10,10a-decahydro-(4aH) -  
 benzo[c]quinoli-zin-3-one;  
 [(4a $\alpha$ ,6a $\beta$ ,10a $\alpha$ ) -3,4,5,6,6a,7,8,9,10,10a-decahydro-(4aH) -  
 benzo[c]quinoli-zin-3-one;]  
 3,4,5,6,6a,7,8,9,10,10a-decahydro-(1H) -benzo[c]quinolizin-3-one;  
 8-chloro-3,4,5,6,6a,7,8,9,10,10a-decahydro-(4aH) -  
 benzo[c]quinolizin-3-one;  
 3,4,5,6,6a,7,8,9,10,10a-decahydro-8-methyl-(4aH) -  
 benzo[c]quinolizin-3-one;  
 3,4,5,6,6a,7,8,9,10,10a-decahydro-4-methyl-(4aH) -  
 benzo[c]quinolizin-3-one;  
 3,4,5,6,6a,7,8,9,10,10a-decahydro-1-methyl-(4aH) -  
 benzo[c]quinolizin-3-one;  
 8-chloro-2,3,5,6,6a,7,8,9,10,10a-decahydro-4-methyl-(1H) -  
 benzo[c]quinolizin-3-one;  
 2,3,5,6,6a,7,8,9,10,10a-decahydro-4,8-dimethyl-(1H) -  
 benzo[c]quinolizin-3-one;  
 8-chloro-2,3,5,6,6a,7,8,9,10,10a-decahydro-1-methyl-(1H) -  
 benzo[c]quinolizin-3-one;  
 2,3,5,6,6a,7,8,9,10,10a-decahydro-1,4-dimethyl-(1H) -

benzo[c]quinolizin-3-one;  
8-chloro-3,4,5,6,6a,7,8,9,10,10a-decahydro-4-methyl-(4aH) -  
benzo[c]quinolizin-3-one;  
3,4,5,6,6a,7,8,9,10,10a-decahydro-4,8-dimethyl-(4aH) -  
benzo[c]quinolizin-3-one;  
8-chloro-3,4,5,6,6a,7,8,9,10,10a-decahydro-1-methyl-(4aH) -  
benzo[c]quinolizin-3-one;  
3,4,5,6,6a,7,8,9,10,10a-decahydro-1,8-dimethyl-(4aH) -  
benzo[c]quinolizin-3-one;  
2,3,5,6,6a,7,8,9,10,10a-decahydro-5-methyl-(1H) -  
benzo[c]quinolizin-3-one;  
8-chloro-2,3,5,6,6a,7,8,9,10,10a-decahydro-5-methyl-(1H) -  
benzo[c]quinolizin-3-one;  
2,3,5,6,6a,7,8,9,10,10a-decahydro-5,8-dimethyl-(1H) -  
benzo[c]quinolizin-3-one;  
2,3,5,6,6a,7,8,9,10,10a-decahydro-4,5-dimethyl-(1H) -  
benzo[c]quinolizin-3-one;  
2,3,5,6,6a,7,8,9,10,10a-decahydro-1,5-dimethyl-(1H) -  
benzo[c]quinolizin-3-one;  
3,4,5,6,6a,7,8,9,10,10a-decahydro-5-methyl-(4aH) -  
benzo[c]quinolizin-3-one;  
8-chloro-3,4,5,6,6a,7,8,9,10,10a-decahydro-5-methyl-(4aH) -  
benzo[c]quinolizin-3-one;  
3,4,5,6,6a,7,8,9,10,10a-decahydro-5,8-dimethyl-(4aH) -  
benzo[c]quinolizin-3-one;  
3,4,5,6,6a,7,8,9,10,10a-decahydro-4,5-dimethyl-(4aH) -  
benzo[c]quinolizin-3-one;  
3,4,5,6,6a,7,8,9,10,10a-decahydro-1,5-dimethyl-(4aH) -  
benzo[c]quinolizin-3-one;  
8-chloro-2,3,5,6,6a,7,8,9,10,10a-decahydro-4,5-dimethyl-(1H) -  
benzo[c]quinolizin-3-one;  
2,3,5,6,6a,7,8,9,10,10a-decahydro-4,5,8-trimethyl-(1H) -  
benzo[c]quinolizin-3-one;  
8-chloro-2,3,5,6,6a,7,8,9,10,10a-decahydro-1,5-dimethyl-(1H) -  
benzo[c]quinolizin-3-one;  
2,3,5,6,6a,7,8,9,10,10a-decahydro-1,4,5-trimethyl-(1H) -  
benzo[c]quinolizin-3-one;

8-chloro-3,4,5,6,6a,7,8,9,10,10a-decahydro-4,5-dimethyl-(4aH) -  
 benzo[c]quinolizin-3-one;  
 3,4,5,6,6a,7,8,9,10,10a-decahydro-4,5,8-trimethyl-(4aH) -  
 benzo[c]quinolizin-3-one;  
 8-chloro-3,4,5,6,6a,7,8,9,10,10a-decahydro-1,5-dimethyl-(4aH) -  
 benzo[c]quinolizin-3-one;  
 3,4,5,6,6a,7,8,9,10,10a-decahydro-1,5,8-trimethyl-(4aH) -  
 benzo[c]quinolizin-3-one;  
 2,3,5,6,6a,7,8,9,10,10a-decahydro-6-methyl-(1H) -  
 benzo[c]quinolizin-3-one;  
 8-chloro-2,3,5,6,6a,7,8,9,10,10a-decahydro-6-methyl-(1H) -  
 benzo[c]quinolizin-3-one;  
 2,3,5,6,6a,7,8,9,10,10a-decahydro-4,6-dimethyl-(1H) -  
 benzo[c]quinolizin-3-one;  
 2,3,5,6,6a,7,8,9,10,10a-decahydro-1,6-dimethyl-(1H) -  
 benzo[c]quinolizin-3-one;  
 3,4,5,6,6a,7,8,9,10,10a-decahydro-6,8-dimethyl-(4aH) -  
 benzo[c]quinolizin-3-one;  
 8-chloro-3,4,5,6,6a,7,8,9,10,10a-decahydro-6,8-dimethyl-(4aH) -  
 benzo[c]quinolizin-3-one;  
 8-chloro-3,4,5,6,6a,7,8,9,10,10a-decahydro-4,6-dimethyl-(4aH) -  
 benzo[c]quinolizin-3-one;  
 3,4,5,6,6a,7,8,9,10,10a-decahydro-1,6-dimethyl-(4aH) -  
 benzo[c]quinolizin-3-one;  
 8-chloro-2,3,5,6,6a,7,8,9,10,10a-decahydro-4,6-dimethyl-(1H) -  
 benzo[c]quinolizin-3-one;  
 2,3,5,6,6a,7,8,9,10,10a-decahydro-4,6,8-trimethyl-(1H) -  
 benzo[c]quinolizin-3-one;  
 8-chloro-2,3,5,6,6a,7,8,9,10,10a-decahydro-1,6-dimethyl-(1H) -  
 benzo[c]quinolizin-3-one;  
 2,3,5,6,6a,7,8,9,10,10a-decahydro-1,4,6-trimethyl-(1H) -  
 benzo[c]quinolizin-3-one;  
 8-chloro-3,4,5,6,6a,7,8,9,10,10a-decahydro-4,6-dimethyl-(4aH) -  
 benzo[c]quinolizin-3-one;  
 3,4,5,6,6a,7,8,9,10,10a-decahydro-4,6,8-trimethyl-(4aH) -  
 benzo[c]quinolizin-3-one;  
 8-chloro-3,4,5,6,6a,7,8,9,10,10a-decahydro-1,6-dimethyl-(4aH) -

benzo[c]quinolizin-3-one;  
3,4,5,6,6a,7,8,9,10,10a-decahydro-1,6,8-trimethyl-(4aH) -  
benzo[c]quinolizin-3-one;  
2,3,5,6,6a,7,8,9,10,10a-decahydro-5,6-dimethyl-(1H) -  
benzo[c]quinolizin-3-one;  
8-chloro-2,3,5,6,6a,7,8,9,10,10a-decahydro-5,6-dimethyl-(1H) -  
benzo[c]quinolizin-3-one;  
2,3,5,6,6a,7,8,9,10,10a-decahydro-4,5,6-trimethyl-(1H) -  
benzo[c]quinolizin-3-one;  
2,3,5,6,6a,7,8,9,10,10a-decahydro-1,5,6-trimethyl-(1H) -  
benzo[c]quinolizin-3-one;  
3,4,5,6,6a,7,8,9,10,10a-decahydro-5,6-dimethyl-(4aH) -  
benzo[c]quinolizin-3-one;  
8-chloro-3,4,5,6,6a,7,8,9,10,10a-decahydro-5,6-dimethyl-(4aH) -  
benzo[c]quinolizin-3-one;  
3,4,5,6,6a,7,8,9,10,10a-decahydro-5,6,8-trimethyl-(4aH) -  
benzo[c]quinolizin-3-one;  
3,4,5,6,6a,7,8,9,10,10a-decahydro-4,5,6-trimethyl-(4aH) -  
benzo[c]quinolizin-3-one;  
2,3,5,6,6a,7,8,9,10,10a-decahydro-1,5,6-trimethyl-(1H) -  
benzo[c]quinolizin-3-one;  
3,4,5,6,6a,7,8,9,10,10a-decahydro-1,5,6-trimethyl-(4aH) -  
benzo[c]quinolizin-3-one;  
8-chloro-2,3,5,6,6a,7,8,9,10,10a-decahydro-4,5,6-trimethyl-(1H) -  
benzo[c]quinolizin-3-one;  
2,3,5,6,6a,7,8,9,10,10a-decahydro-4,5,6,8-tetramethyl-(1H) -  
benzo[c]quinolizin-3-one;  
8-chloro-2,3,5,6,6a,7,8,9,10,10a-decahydro-1,5,6-trimethyl-(1H) -  
benzo[c]quinolizin-3-one;  
2,3,5,6,6a,7,8,9,10,10a-decahydro-1,4,5,6-tetramethyl-(1H) -  
benzo[c]quinolizin-3-one;  
8-chloro-3,4,5,6,6a,7,8,9,10,10a-decahydro-4,5,6-trimethyl-(4aH) -  
benzo[c]quinolizin-3-one;  
3,4,5,6,6a,7,8,9,10,10a-decahydro-4,5,6,8-tetramethyl-(4aH) -  
benzo[c]quinolizin-3-one;  
8-chloro-3,4,5,6,6a,7,8,9,10,10a-decahydro-1,5,6-trimethyl-(4aH) -  
benzo[c]quinolizin-3-one;

3,4,5,6,6a,7,8,9,10,10a-decahydro-1,5,6,8-tetramethyl-(4aH) -  
 benzo[c]quinolizin-3-one;  
 5,6,6a,7,8,9,10,10a-octahydro-(3H) -benzo[c]quinolizin-3-one;  
 8-chloro-5,6,6a,7,8,9,10,10a-octahydro-(3H) -benzo[c]quinolizin-3-  
 one;  
 5,6,6a,7,8,9,10,10a-octahydro-8-methyl-(3H) -benzo[c]quinolizin-3-  
 one;  
 5,6,6a,7,8,9,10,10a-octahydro-4-methyl-(3H) -benzo[c]quinolizin-3-  
 one;  
 8-chloro-5,6,6a,7,8,9,10,10a-octahydro-4-methyl-(3H) -  
 benzo[c]quinolizin-3-one;  
 5,6,6a,7,8,9,10,10a-octahydro-4,8-dimethyl-(3H) -  
 benzo[c]quinolizin-3-one;  
 2,3,5,6,7,8,9,10-octahydro-(1H) -benzo[c]quinolizin-3-one;  
 8-chloro-2,3,5,6,7,8,9,10-octahydro-(1H) -benzo[c]quinolizin-3-  
 one;  
 2,3,5,6,7,8,9,10-octahydro-8-methyl-(1H) -benzo[c]quinolizin-3-  
 one;  
 2,3,5,6,6a,7,8,9-octahydro-(1H) -benzo[c]quinolizin-3-one;  
 8-chloro-2,3,5,6,6a,7,8,9-octahydro-(1H) -benzo[c]quinolizin-3-  
 one;  
 2,3,5,6,6a,7,8,9-octahydro-8-methyl-(1H) -benzo[c]quinolizin-3-  
 one;  
 4a-benzyl-3,4,5,6,6a,7,8,9,10,10a-decahydro-(4aH) -  
 benzo[c]quinolizin-3-one;  
 4a-benzyl-8-chloro-3,4,5,6,6a,7,8,9,10,10a-decahydro-(4aH) -  
 benzo[c]quinolizin-3-one;  
 4a-benzyl-3,4,5,6,6a,7,8,9,10,10a-decahydro-8-methyl-(4aH) -  
 benzo[c]quinolizin-3-one;  
 4a-benzyl-3,4,5,6,6a,7,8,9,10,10a-decahydro-4-methyl-(4aH) -  
 benzo[c]quinolizin-3-one;  
 4a-benzyl-3,4,5,6,6a,7,8,9,10,10a-decahydro-1-methyl-(4aH) -  
 benzo[c]quinolizin-3-one;  
 3,4,5,6,6a,7,8,9,10,10a-decahydro-4a-(4-pyridyl)methyl-(4aH) -  
 benzo[c]quinolizin-3-one;  
 8-chloro-3,4,5,6,6a,7,8,9,10,10a-decahydro-4a-(4-pyridyl)-methyl-  
 (4aH) -benzo[c]quinolizin-3-one;

3,4,5,6,6a,7,8,9,10,10a-decahydro-8-methyl-4a-(4-pyridyl)methyl-(4aH)-benzo[c]quinolizin-3-one;

3,4,5,6,6a,7,8,9,10,10a-decahydro-4-methyl-4a-(4-pyridyl)methyl-(4aH)-benzo[c]quinolizin-3-one[;].

3,4,5,6,6a,7,8,9,10,10a-decahydro-1-methyl-4a-(4-pyridyl)methyl-(4aH)-benzo[c]quinolizin-3-one;

4. (canceled)

5. (canceled)

6. (canceled)

7. (canceled)

8. (canceled)

9. (canceled)

10. (previously presented) A pharmaceutical composition wherein the active principle is a compound of formula (I) according to Claim 1 or mixtures thereof in combination with [the] suitable pharmaceutically acceptable excipients.

11. (canceled)

12. (canceled)

13. (canceled)

14. (canceled)

15. (canceled)

16. (canceled)

17. (canceled)

18. (canceled)

19. (canceled)

20. (canceled)

21. (canceled)

22. (canceled)

23. (canceled)

24. (canceled)

25. (canceled)

26. (canceled)

*canceled claim*


27. (previously presented) A method for the inhibition of 5 $\alpha$  reductase-I and/or 5 $\alpha$  reductase-II iso-enzymes as defined in claim 13 where the pathology is selected from the group consisting of acne, baldness, prostatic cancer and prostatic



hypertrophy in men and hirsutism in women.

*administration of a therapeutically effective amount to a host in need thereof.*

28. (amended) A fully and partially reduced benzo(c)quinolizine compound of formula (I):



wherein:

R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> and R<sub>6</sub>, which are the same or different, are chosen from the group consisting of: H, C<sub>1-8</sub> alkyl, C<sub>2-8</sub> alkenyl, C<sub>2-8</sub> alkynyl, cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, norbornane, camphane, adamantane, phenyl, biphenyl or naphthyl;

R<sub>5</sub> is chosen from the group consisting of: H, C<sub>1-8</sub> alkyl, C<sub>1-8</sub>alkyl-phenyl, biphenyl, naphthyl, COOR, CN or phenyl;

X is chosen from the group consisting of: O, C(=O)R, COOR, NO<sub>2</sub>, and CONR', wherein R and R' are as above defined;

Q is chosen from the group consisting of single-bond, C<sub>1-8</sub> alkyl, C<sub>2-8</sub> alkenyl, C<sub>2-8</sub> alkynyl, cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, norbornane, camphane, adamantane, CO, CONR, and NR, where R is as above defined;


W is chosen from the group consisting of H, C<sub>1-8</sub> alkyl, C<sub>2-8</sub> alkenyl, C<sub>2-8</sub> alkynyl, cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, norbornane, camphane, adamantane, trifluoromethyl, C<sub>1-8</sub> alkoxy, C<sub>1-8</sub> alkoxy-C<sub>1-8</sub> alkyl, phenyl, biphenyl, naphthyl-C<sub>1-8</sub> alkyl, phenyl, biphenyl, naphthyl, phenyloxy, biphenyloxy, naphthyloxy, phenylamino, biphenylamino, naphthylamino, C<sub>1-8</sub> alkyl-carbonyl, phenylcarbonyl, biphenylcarbonyl, naphthylcarbonyl, phenylcarboxyl,

biphenylcarboxyl, naphthylcarboxyl, phenylcarboxamide, biphenylcarboxamide, naphthylcarboxamide, halogen, CN, NRR' where R and R' are as above defined;

n is an integer comprised between 1 and 4;

the symbol ----- means that the corresponding bonds a, b, c, d, e, f, g, h and i are single or double bonds, with the proviso that when b or f are a double bond, the group R<sub>5</sub> is absent; their pharmaceutically acceptable salts and esters.

29. (new) A fully and partially reduced benzo(c)quinolizine compound of formula (1):



wherein:

R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> and R<sub>6</sub>, which are the same or different, are chosen from the group consisting of: H, C<sub>1-8</sub> alkyl, C<sub>2-8</sub> alkenyl, C<sub>2-8</sub> alkynyl, cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, norbornane, camphane, adamantane, phenyl, biphenyl or naphthyl;

R<sub>5</sub> is chosen from the group consisting of: H, C<sub>1-8</sub> alkyl, C<sub>1-8</sub>alkyl-phenyl, biphenyl, naphthyl, COOR, CN, phenyl;

X is chosen from the group consisting of: O, C(=O)R, COOR, NO<sub>2</sub>, and CONNR', wherein R and R' are as above defined;

Q is chosen from the group consisting of single-bond, C<sub>1-8</sub> alkyl, C<sub>2-8</sub> alkenyl, C<sub>2-8</sub> alkynyl, cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, norbornane, camphane, adamantane, CO, CONR, and NR, where R is as above defined;

W is chosen from the group consisting of H, C<sub>1-8</sub> alkyl, C<sub>2-8</sub>